Biosimilars Market Size Worth USD 73.24 Billion By 2036 | CAGR: 6.9%

The global biosimilars market size was valued at USD 35.22 billion in 2025 and is expected to reach USD 73.24 billion by 2036, growing at a CAGR of 6.9% from 2026 to 2036, according to a new study by Polaris Market Research & Consulting, Inc. The report, "Biosimilars Market Size, Share, Trends, Industry Analysis Report: By Drug Class, By Therapeutic Area, By Interchangeability Status, By Distribution Channel, and By Region, Market Forecast, 2026 to 2036," examines growth factors, key segments, competitive strategies, drug pipeline activity and regional outlook.

The market is expanding as patent expiries create opportunities across high-value biologics. Keytruda and Keytruda Qlex generated about USD 31.7 billion for Merck in 2025, and Merck says biosimilar competition could begin in December 2028, when the primary compound patent expires. More than ten developers already have pembrolizumab biosimilars in clinical trials, and Amgen has submitted an FDA application for a nivolumab biosimilar. Ustekinumab, aflibercept, and denosumab shaped the 2024–2025 wave, while omalizumab, pembrolizumab, and high-dose aflibercept are driving the next development cycle. The FDA had approved a total of 90 biosimilars through the end of 2025 and several checkpoint inhibitor programs are moving toward potential commercialization.

Pricing and pharmacy rules decide who wins after approval. The FDA approved 18 biosimilars in 2025, and interchangeable products can be substituted at the pharmacy counter where state law allows. A lower list price does not always turn into share, and the report shows where rebates and formulary placement change the outcome.

Deals are also reshaping who reaches which market. Licensing partnerships now link developers in Asia with commercial partners in Europe, Japan and the Middle East, splitting development, manufacturing and sales across regions.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Biosimilars Market Report

What the full report answers

• Which reference biologics lose exclusivity next, and which developers are closest to FDA approval
• How interchangeable designations change formulary substitution, and where list price cuts fail to reach net price
• How licensing deals are moving development and manufacturing across regions
• Which drug classes, therapeutic areas and regions are forecast to grow fastest through 2036

Biosimilars Market Report Highlights

• Monoclonal antibodies led the drug class segment in 2025 with 46.18% share, due to established molecules such as adalimumab, approval activity and established competition across major biologics.
• Oncology is projected to register a CAGR of 8.36% through 2036 due to expanding pembrolizumab, nivolumab, and other biosimilar programs move toward regulatory decisions.
• North America accounted for 34.68% of the market in 2025, attributed to the high FDA approval activity and increasing adoption of interchangeable biosimilars.
• Asia Pacific is projected to grow fastest, at 8.47% CAGR from 2026 to 2036, as regional manufacturers license products to global commercial partners.
• Major players include Amgen Inc., Sandoz Group AG, Pfizer Inc., Celltrion, Inc., Samsung Bioepis Co., Ltd., Biocon Biologics Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Accord BioPharma Inc.

Polaris Market Research has segmented the Biosimilars Market report based on drug class, therapeutic area, interchangeability status, distribution channel, and region:

By Drug Class Outlook (Revenue, USD Billion, 2021–2036)

• Monoclonal Antibodies
• TNF-Alpha Inhibitors
• Insulins
• Granulocyte Colony-Stimulating Factor (G-CSF) Agents
• VEGF Inhibitors
• Others

By Therapeutic Area Outlook (Revenue, USD Billion, 2021–2036)

• Autoimmune and Inflammatory Disorders
• Oncology
• Ophthalmology
• Diabetes Mellitus
• Others

By Interchangeability Status Outlook (Revenue, USD Billion, 2021–2036)

• Interchangeable Biosimilars
  • Adalimumab biosimilars
  • Checkpoint Inhibitor and Omalizumab Biosimilars
• Non-Interchangeable Biosimilars

By Distribution Channel Outlook (Revenue, USD Billion, 2021–2036)

• Hospital Pharmacies
• Retail and Specialty Pharmacies
• Online / Cash-Pay Platforms

By Region Outlook (Revenue – USD Billion, 2021–2036)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Want to see the drug pipeline table, pricing benchmarks and regional outlook before you buy? Download a free sample or talk to a Polaris analyst about a custom scope by drug class, therapeutic area or region.